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incidence
The incidence of malignant glioma is approximately 5/100 000.
Malignant glioma may develop at all ages, the peak incidence
being in the fifth and sixth decades of life.
diagnosis
Malignant glioma comprises glioblastoma [World Health
Organization (WHO) grade IV], anaplastic astrocytoma (WHO
grade III), mixed anaplastic oligoastrocytoma (WHO grade III)
and anaplastic oligodendroglioma (WHO grade III).
Diagnosis after biopsy or tumor resection is made according to
the revised WHO classification. Prognosis depends on tumor
grade and histology. Glioblastoma carries the worst prognosis,
whereas pure oligodendroglioma tends to have a better
outcome and improved response to therapy. Prognosis of
mixed anaplastic oligoastrocytoma and anaplastic astrocytoma
is intermediate between glioblastoma and pure anaplastic
oligodendroglioma.
molecular markers
Genetic loss on chromosomes 1p/19q [loss of heterozygosity
(LOH) 1p/19q], recently recognized as a chromosomal
translocation has been suggested as a marker for responsiveness
to chemotherapy. However, it describes a distinct tumor entity
with a prolonged natural history irrespective of treatment,
its chemo-responsiveness may be due to the high correlation
with methyl-guanine methyl transferase (MGMT) promoter
methylation. LOH 1p/19q should be performed to support
a diagnosis of oligodendroglioma.
Epigenetic silencing of the MGMT gene promoter by
methylation indicates a partial inability of the tumor to repair
the chemotherapy-induced DNA damage. In retrospective
analyses it has been strongly correlated with outcome to
alklyating agent chemotherapy [II, B]. Alternatively, MGMT
determination by immunohistochemistry has been suggested,
however this method lacks standardization, reproducibility and
correlation with clinical outcome [III, C]. Short of established
alternative treatments, and in the absence of clinical
consequences, the routine determination of the MGMT
promoter methylation status does not (yet) add to routine
patient management [V, D].
staging and risk assessment
Staging includes imaging of the brain, ideally by magnetic
resonance (MRI). Extent of resection and determination of
residual disease should be assessed by within 24–48 h after
surgery. Lumbar puncture is generally not necessary, and
staging of other organs is not needed.
Lower tumor grade, tumor resection, younger age (<50
years), good performance status, and an intact neurological
function, have been identified as more favorable prognostic
factors.
treatment plan
Patients should be evaluated by a specialized multidisciplinary
team. Special consideration needs to be given to performance
status and neurological function. High doses of corticosteroids
(usually dexamethasone 8–16 mg/day) will allow the rapid
reduction of tumor-associated edema and improve clinical
symptoms. Patient glucose level needs to be monitored, there is
no need for prolonged steroid therapy after tumor resection or
prophylaxis during radiotherapy: Antiepileptic therapy is
indicated in patients presenting with an initial seizure, however
prophylactic antiepileptic therapy before or after surgery is
not needed in asymptomatic patients [III, C]. After tumor
resection, the indication for anti-seizure therapy should be
revisited. First generation antiepileptic drugs (phenytoin,
carbamazepin, phenobarbital and their derivates) are strong
inducers of the hepatic metabolism and may interfere with
many concomitant medications, including many commonly
used chemotherapy agents (but not with temozolomide).
newly diagnosed patients
Surgery is commonly the initial therapeutic approach for tumor
debulking and obtaining tissue for diagnosis. Tumor resection
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is of prognostic value; it may be beneficial to attempt maximal
tumor resection provided that neurological function is not
compromised by the extent of resection [II, C]. Implantation of
chemotherapy-impregnated wafers (carmustine polymer) into
the resection cavity before radiotherapy has shown to improve
marginally the median survival compared with
radiotherapy alone [II, B], however no data are available to
compare with standard temozolomide/radiotherapy (TMZ/RT,
see below).
Fractionated focal radiotherapy (60 Gy, 30–33 fractions of
1.8–2 Gy, or equivalent doses/fractionations) is the standard
treatment after resection or biopsy [I, A]. Escalating doses
beyond 60 Gy has not been shown to be of value. In elderly
patients or patients with a low performance status, shorter
hypofractionated regimens (e.g. 40 Gy in 15 fractions) are
commonly proposed [II, B]. Radiotherapy (28·1.8 Gy, 50 Gy)
in patients >70 years of age was superior to best supportive care
alone in a randomized phase III trial [II, B]. Exclusive
chemotherapy (usually temozolomide) has been proposed for
elderly patients, but no randomized data is yet available [IV, B]
Glioblastoma (WHO grade IV). Concomitant and adjuvant
temozolomide (TMZ) chemotherapy significantly improved
median, 2- and 5-year survival in a large randomized trial, and
is the current standard of care for patients with glioblastoma up
to age 70 [I, A]. No randomized trial data is available for elderly
patients (>70 years) with a good performance status.
Temozolomide is administered daily during radiotherapy, and
for 5 days every 4 weeks for six cycles as maintenance
(adjuvant) treatment after the end of radiation. Selecting
patients likely to benefit from therapy on the basis of MGMT
gene promoter methylation has been suggested [II, B], and
prospective validation studies have completed accrual.
Adjuvant chemotherapy with procarbazine, lomustine and
vincristine (PCV regimen) has failed to improve survival in
prospective randomized studies, both in grade IV and in grade
III tumors [I, A]. Nevertheless, based on a large meta-analysis
[I, A] nitrosourea-based chemotherapy may marginally
improve survival in selected patients.
Anaplastic astrocytoma, oligoastrocytoma and
oligodendroglioma (WHO grade III). Anaplastic astrocytoma
and oligoastrocytoma have a more protracted clinical course.
Standard therapy consists of adjuvant radiotherapy up to 60 Gy
after surgery. The value of concomitant and/or maintenance
chemotherapy with temozolomide has not yet been tested
prospectively [V, D]. Randomized clinical trials did not
demonstrate prolonged survival with (neo-)adjuvant PCV
chemotherapy [procarbazine, lomustine (CCNU)] in newly
diagnosed anaplastic oligoastrocytoma and oligodendroglioma
[I, B], although progression-free survival was prolonged.
Oligodendroglioma characterized by LOH 1p/19q have
a distinct and much more favorable natural history. Early
administration of adjuvant chemotherapy before or after
radiation did not impact overall survival, despite the exquisite
chemo-responsiveness previously described for these tumors
[II, B]. Time to failure of both chemotherapy and radiation was
similar whether patients are initially treated with chemotherapy
(and receiving RT at first progression) or whether patients are
treated with initial RT (and administration of chemotherapy at
progression) in a randomized trial [II, B]. No difference of
efficacy was apparent between PCV or temozolomide
chemotherapy [III, B].
recurrent disease
Some benefit of chemotherapy has been shown for patients
with an adequate performance status who have not received
prior adjuvant cytotoxic therapy. Anaplastic astrocytomas are
more likely than glioblastoma to respond to temozolomide
chemotherapy [III, B]. For patients progressing after prior
chemotherapy, there is no established chemotherapy regimen
available and patients are best treated within investigational
clinical protocols. Single-agent nitrosourea therapy may
improve tumor control in some patients, while randomized
trials have failed to demonstrate measurable anti-tumor efficacy
of epidermal growth factor receptor (EGFR) inhibition by
erlotinib or platelet-derived growth factor receptor
(PDGFR) inhibition by imatinib in an unselected patient
population [II, C]. High response rates and a steroid-sparing
effect have been observed with the administration of
bevacizumab (6 irinotecan), however, the effect is frequently
short-lived and may be largely due to changes in vascular
permeability without necessarily translating into a prolonged
survival [III, C].
Repeat surgery and implantation of chemotherapy-
impregnated polymers may prolong survival in selected patients
[II, B].
response evaluation
If response is evaluated, it should be done with MRI. Contrast
enhancement and presumed tumor progression on imaging 4–8
weeks after the end of radiotherapy may be an imaging artefact
(pseudoprogression) and should be re-evaluated 4 weeks later
with a second MRI. In case of doubt in patients with early
progression after the end of radiotherapy, chemotherapy
should be pursued as planned.
Response to chemotherapy is evaluated according to the
WHO criteria, but should also include an assessment of
neurological function and corticosteroid use (Macdonald
criteria). The rate of patients alive and progression free at 6
months (PFS6mo) has been recognized as a valid endpoint and
also includes patients who benefit from therapy by disease
stabilization. However, with the frequent use of anti-angiogenic
and vasculature modifying agents this endpoint may need to be
revisited.
follow-up
Follow-up consists of a clinical evaluation with particular
attention to neurological function, seizures or seizure
equivalents and corticosteroid use. Patients should be tapered
off steroid use as early as possible. Venous thrombotic events
occur frequently in patients with unresected or recurrent
tumors.
Laboratory tests are not indicated unless the patient is
receiving chemotherapy (blood counts), corticosteroids
(glucose) or antiepileptic drugs (blood count, liver function
tests).
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For imaging, MRI is recommended. Repeat MRI every 3–4
months is standard practice outside clinical trials, unless more
frequent monitoring is clinically indicated.
note
Levels of Evidence [I–V] and Grades of Recommendation [A–
D] as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts and
the ESMO faculty.
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